Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) was up 0.6% during mid-day trading on Thursday . The company traded as high as $6.53 and last traded at $6.26. Approximately 6,932,748 shares traded hands during trading, an increase of 4% from the average daily volume of 6,639,027 shares. The stock had previously closed at $6.22.
Analyst Ratings Changes
Several brokerages have recently issued reports on RXRX. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Leerink Partners dropped their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group reduced their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $9.25.
Check Out Our Latest Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Trading Down 1.0 %
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business’s revenue for the quarter was up 147.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.43) EPS. Sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.
Insider Transactions at Recursion Pharmaceuticals
In other news, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $6.16, for a total transaction of $123,200.00. Following the transaction, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,697,960.96. The trade was a 2.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $7.00, for a total value of $42,000.00. Following the transaction, the chief operating officer now owns 521,138 shares in the company, valued at $3,647,966. This represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 107,788 shares of company stock worth $724,691. 15.75% of the stock is owned by insiders.
Hedge Funds Weigh In On Recursion Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Franklin Resources Inc. raised its stake in Recursion Pharmaceuticals by 58.9% during the third quarter. Franklin Resources Inc. now owns 18,963 shares of the company’s stock worth $127,000 after acquiring an additional 7,027 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in Recursion Pharmaceuticals in the third quarter valued at about $89,000. Geode Capital Management LLC increased its holdings in shares of Recursion Pharmaceuticals by 13.7% during the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after buying an additional 656,003 shares in the last quarter. Barclays PLC raised its stake in shares of Recursion Pharmaceuticals by 53.9% in the third quarter. Barclays PLC now owns 697,432 shares of the company’s stock valued at $4,596,000 after acquiring an additional 244,278 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Recursion Pharmaceuticals in the 3rd quarter worth approximately $692,000. 89.06% of the stock is owned by institutional investors.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Read More
- Five stocks we like better than Recursion Pharmaceuticals
- 3 Fintech Stocks With Good 2021 Prospects
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- What Are Dividend Contenders? Investing in Dividend Contenders
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.